Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China

BERWYN, Pa.--(BUSINESS WIRE)--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, and central nervous system (CNS) disorders, today announced that the Company has engaged New England Investors, LLC to serve as the out-licensing advisor for Envelta in the People’s Republic of China. Envelta is Virpax’s non-opioid pain product candidate for acute and chronic pain including non-cancer pain. “
http://dlvr.it/ShkVCd

Comments

Popular posts from this blog

Hempy 2014!

Coming Out of the Pot Closet

PureTech Provides End of Year Report on Key Progress